HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA ISO Data On CBD Safety In Supplements, Sees Potential As Well As Risks

Executive Summary

There's a reason the FDA continues accepting comments on questions about using hemp- and cannabis-derived ingredients in products other than drugs months after the comment period closed. "It's safe to say say that in 4,500 comments, we did not receive a lot of hard data around the issues that we specifically requested comments on," says Sharon Mayl, senior advisor for policy in the commissioner's office.

You may also be interested in...



Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

Cannabidiols In Supplements Unlike CBD Isolate Approved As Drug, Attorneys Say

As many as 100 ingredients are identified in hemp and cannabis plants, and FDA could be impeding even faster growth of CBD-containing supplement and food market by insisting that all those substances are the same as the CBD isolate active ingredient in Epidiloex, say FDLI's first conference entirely on regulation of cannabis and hemp products market.

CBD Products For Children Could Connect The Dots To FDA's Problem For Congress

In addition to FDA and FTC attention, pediatric claims by Rooted Apothecary could get attention of US lawmakers, who FDA is asking to authorize it to more directly enforce against adulterated supplements. Violative claims include “Increasing evidence suggests that CBD oil is a powerful option for pain and autism. It seems like an attractive and safe option for children.”

Related Content

Topics

UsernamePublicRestriction

Register

RS149436

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel